Program Co-leaders:
A critical mission of the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center is to improve patient outcomes through the development of novel therapies and therapeutic strategies. To that end, the Cancer Therapeutics (CT) Program's develops and tests new therapies for solid tumors and hematologic malignancies.
The CT Program consists of members from five schools of the University of Maryland, including the School of Medicine (representing several departments) and the School of Pharmacy. Program members are supported by many individual peer-reviewed grants. The unifying theme of this Program is to build translational clinical trials based on innovative and novel laboratory research projects.
Program Goal
To develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical and clinical research.
Program Aims
- AIM 1: Molecular targeting—Development and Validation
To advance new cancer therapies through the interrogation and validation of novel molecular targets using in vitro and in vivo laboratory studies. - AIM 2: Novel treatment delivery strategies
To investigate the development of new technologies for cancer therapy delivery, including molecular carriers, nanotechnology, and novel radiation therapy approaches. - AIM 3: Treatment—Clinical testing
Design and conduct early phase trials to translate basic research discoveries into the clinic and enable the conduct of late-stage trials that set new practice paradigm and standards.
CT program activities are greatly enhanced by extensive interactions with other cancer center programs. Program members are frequent users of Cancer Center Shared Resources. The Cancer Center also supports monthly Program meetings and yearly Program scientific retreats. The increasing numbers of cancer-directed translational and clinical studies developed by program members is a manifestation of the success of this program.